The Janus Face of CD4+CD25+ Regulatory T Cells in Cancer and Autoimmunity

Author(s): S. Danese, S. Rutella.

Journal Name: Current Medicinal Chemistry

Volume 14 , Issue 6 , 2007

Submit Manuscript
Submit Proposal

Abstract:

Regulatory T cells (Treg) encompass a heterogeneous family of T cells implicated in maintenance of tolerance to self antigens. Treg cells might be qualitatively and/or quantitatively deficient in human autoimmune diseases, including multiple sclerosis, graft versus host disease, systemic lupus erythematosus, type I diabetes, and rheumatoid arthritis. In animal models of autoimmunity, infusion of ex vivo-expanded Treg cells and/or in vivo enhancement of Treg cell suppressor function by pharmacological agents and cytokines attenuate disease manifestations and restore tolerance. However, Treg cells represent a double-edged sword, as Treg cells with specificity for tumour-associated antigens contribute to cancer pathogenesis and progression. In vivo depletion of Treg cells by monoclonal antibodies and/or selected drugs is an encouraging therapeutic strategy which improves tumour eradication in animal models of cancer. In addition, elimination and/or functional inactivation of Treg cells might boost anti-tumour immunity in tumour-bearing hosts receiving anti-cancer vaccination. The present review discusses Treg cell manipulation as a novel therapeutic strategy in cancer and autoimmunity, conditions characterised by a common regulatory basis.

Keywords: Regulatory T cell, cancer, autoimmunity, cytokines, dendritic cell

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 6
Year: 2007
Page: [649 - 666]
Pages: 18
DOI: 10.2174/092986707780059599
Price: $58

Article Metrics

PDF: 3